A wave of new innovations from several companies, including Biogen, Eli Lilly, and Eisai, have started to show promise in slowing down the harmful transition of Alzheimer's disease into its most debilitating stages. But some have questioned whether these treatments would make a meaningful difference for Alzheimer's patients or to society at large.
Read Full Article »
